Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib DDI with Fexofenadine in EGFRm NSCLC
NCT02908750Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration (Cmax) of Fexofenadine and Area Under the Plasma Concentration-Time Curve (AUC) of Fexofenadine. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02908750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908750.